Everything below concerns Phase 3 trial. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Updated 2026-01-06. Numbers and descriptions here follow the published literature rather than marketing material.
Pharmacodynamic studies show that tesamorelin reduces visceral adipose tissue more than subcutaneous adipose tissue in the studied population. This selectivity may relate to differences in blood flow and hormone sensitivity between fat depots. Effects on glucose metabolism and insulin sensitivity have been investigated, with some trials reporting modest changes and others showing stability. The precise relationship between growth hormone exposure, IGF-1 levels, and visceral fat loss remains an active area of analysis.
Tesamorelin binds to growth hormone-releasing hormone receptors on somatotroph cells in the anterior pituitary. Receptor activation increases intracellular cyclic AMP and promotes synthesis and secretion of growth hormone. Because the peptide mimics endogenous GHRH, it amplifies the normal pulsatile release of growth hormone rather than providing exogenous growth hormone directly. This upstream action distinguishes tesamorelin from recombinant growth hormone preparations and from growth hormone secretagogues that act at different receptors.
Stimulated growth hormone release leads to hepatic production of insulin-like growth factor 1, a key mediator of many growth hormone effects. In clinical studies, tesamorelin increased IGF-1 levels in a dose-dependent manner, although the response varies among individuals. The drug's effect on visceral fat is thought to involve growth hormone-mediated lipolysis and altered adipocyte metabolism. Muscle mass and lean body mass have also been assessed as secondary outcomes, but changes are generally smaller and less consistent than fat reductions.
After injection, the peptide binds receptors on somatotroph cells in the anterior pituitary. Receptor activation raises intracellular cyclic AMP and triggers release of stored growth hormone into the bloodstream. Because the compound works through the body's own regulatory system, growth hormone pulses retain much of their normal feedback control. Repeated administration also raises insulin-like growth factor 1, a hormone produced mainly in the liver. Investigators treat that rise as a marker that the pituitary axis has been engaged.
Clinical study of tesamorelin has centered on adults with HIV-associated lipodystrophy, a condition in which abdominal fat accumulates while peripheral fat is lost. In controlled trials, treated participants showed reductions in visceral adipose tissue measured by imaging, alongside modest shifts in some lipid values. Effects on subcutaneous fat were smaller and less consistent across studies. Whether these changes translate into fewer cardiovascular events remains an open question, because the trials were not designed or powered to answer it.
| Property | Value | Notes |
|---|---|---|
| Primary target | Growth hormone-releasing hormone receptor | Located on anterior pituitary somatotroph cells. |
| Receptor class | G protein-coupled receptor | Activation increases intracellular cyclic AMP. |
| Main downstream hormone | Growth hormone and insulin-like growth factor 1 | Growth hormone release precedes IGF-1 elevation. |
| Primary studied effect | Reduction in visceral adipose tissue | Measured by computed tomography in clinical trials. |
| Approximate half-life | 26–38 minutes after subcutaneous administration | Values vary by assay and study population. |
Because growth hormone is released in pulses, single measurements can misrepresent overall secretion. Investigators sometimes use repeated sampling or overnight profiles to capture the pattern rather than a single value. Provocative testing, in which a stimulus is given and the response is tracked over time, offers another way to characterize the axis. Each approach carries trade-offs between sensitivity, burden on the participant, and the influence of non-target variables.
Insulin-like growth factor 1 is produced largely in the liver in response to growth hormone signaling. Its concentration shifts over days rather than minutes, which makes it practical for tracking changes across a study period. Interpretation still depends on age, nutritional status, and concurrent illness, all of which independently affect the marker. Reference ranges are therefore stratified, and comparisons are usually made within an individual over time rather than against a single population threshold.
Regulatory approval in the United States came in 2010, when the Food and Drug Administration cleared the peptide for the reduction of excess abdominal fat in adults with HIV infection and associated lipodystrophy. The decision rested mainly on two randomized phase 3 trials that enrolled roughly eight hundred patients and ran for twenty-six weeks. Participants receiving active drug showed substantially greater declines in visceral adipose tissue than those receiving placebo, while total body weight changed comparatively little. A reformulated presentation was later approved, and the product has remained a niche therapy rather than a general weight-loss agent.
Tesamorelin occupies a narrow position among agents that act on the growth hormone axis. Unlike growth hormone itself, which is given as replacement, it stimulates the pituitary to release the hormone in pulses, so the downstream increase in insulin-like growth factor 1 depends on intact somatotroph function. Other peptides in the same family include shorter GHRH fragments and synthetic secretagogues with different stability profiles. Several points remain unresolved, including whether the reduction in visceral fat translates into fewer cardiovascular events, what happens to metabolic markers after long-term use, and how the drug compares with lifestyle or surgical approaches.
Tesamorelin is a synthetic peptide that belongs to the growth hormone-releasing hormone family and contains the same forty-four amino acid sequence as endogenous GHRH, extended at the amino terminus by a trans-3-hexenoyl group. That small fatty acid modification protects the peptide from rapid cleavage by dipeptidyl peptidase-4, the enzyme that shortens the half-life of native GHRH to only a few minutes. Chemically the compound is produced by solid-phase peptide synthesis, purified by chromatography, and supplied as a sterile lyophilized powder for reconstitution.
== Algorithm == Sequest identifies each tandem mass spectrum individually. The software evaluates protein sequences from a database to compute the list of peptides that could result from each. The peptide's intact mass is known from the mass spectrum, and Sequest uses this information to determine the set of candidate peptides sequences that could meaningfully be compared to the spectrum by including only those near the mass of the observed peptide ion. For each candidate peptide, Sequest projects a theoretical tandem mass spectrum, and Sequest compares these theoretical spectra to the observed tandem mass spectrum by the use of cross correlation. The candidate sequence with the best matching theoretical tandem mass spectrum is reported as the best identification for this spectrum.
=== Vector transmission === Diseases transmitted from human to human indirectly, i.e. malaria spread by way of mosquitoes, are transmitted through a vector. In these cases, the infection transfers from human to insect and an epidemic model must include both species, generally requiring many more compartments than a model for direct transmission.
Wallace's testimony. 12 September – Secondary school teachers affiliated with the Post Primary Teachers' Association vote to reject the Government's pay offer. The union announces that partial strikes will be held between 15 and 18 September. 13 September: About 20,000 Palestinian solidarity supporters hold a "March for Humanity" in Central Auckland calling for the New Zealand Government to sanction Israel over its conduct in the Gaza war. 50 pro-Israel counter-demonstrators also stage march and haka (ka mate). Strong overnight winds cause power outages in the Coromandel peninsula and the Western Bay of Plenty. Power utility company Powerco reports that 13,456 customers are left without power. 16 September – Carter Holt Harvey confirms plans to close its Tokoroa plywood manufacturing plant, affecting 119 full-time jobs. 17 September: Several nurses turn their back on Health Minister Simeon Brown during the New Zealand Nurses Organisation's annual conference in Wellington to protest hospital understaffing and poor pay conditions. Shane Jones is elected by the New Zealand First parliamentary caucus as the party's deputy leader. Strong winds cause eight vegetation fires in the Canterbury Region, including a large 30 hectare fire in Southbridge. The New Zealand Parliament passes urgent legislation preventing convicted abusers from adopting children from other countries. 18 September – Griffin's Snacks proposes closing its Proper Crisps factory in Nelson, potentially affecting 82 jobs.
== T == Tactile agnosia The inability to recognize objects by touch, despite intact somatosensation. Often results from lesions in the parietal lobe. Tardive dyskinesia A neurological disorder characterized by involuntary, repetitive movements, typically of the face or limbs. Often a side effect of long-term use of antipsychotic medications. Tau protein A microtubule-associated protein involved in stabilizing neuronal cytoskeletons. Abnormal tau aggregation is a hallmark of Alzheimer's disease and other tauopathies. Tectum The dorsal part of the midbrain, containing structures such as the superior colliculus and inferior colliculus, involved in visual and auditory reflexes. Telencephalon The anterior part of the forebrain that develops into the cerebral hemispheres. It contains the cerebral cortex, basal ganglia, and limbic system structures. Temporal lobe A lobe of the cerebral cortex involved in auditory processing, language comprehension, memory, and emotion. Thalamus A deep brain structure that serves as a major relay center, transmitting sensory and motor signals to the cerebral cortex. It also plays a role in consciousness and alertness. Theta wave A type of brainwave oscillation in the 4–8 Hz range, typically associated with light sleep, meditation, and memory encoding processes. Third ventricle A narrow cavity in the brain located between the two halves of the diencephalon, connected to the lateral and fourth ventricles and filled with cerebrospinal fluid. Thoracic spinal cord The portion of the spinal cord that corresponds to the thoracic vertebrae.
Sources: en.wikipedia.org
As of May 2021, Pakistan operates six licensed commercial nuclear power plants. The Pakistan Atomic Energy Commission (PAEC) oversees these plants, while the Pakistan Nuclear Regulatory Authority ensures their safe operation. These plants contribute approximately 5.8% to Pakistan's electricity supply, while fossil fuels (crude oil and natural gas) provide 64.2%, hydroelectric power provides 29.9%, and coal contributes 0.1%. The KANUPP-I, Pakistan's first commercial nuclear power plant, was supplied by Canada in 1971. Sino-Pakistani nuclear cooperation began in the 1980s, leading to the establishment of CHASNUPP-I. In 2005, both countries proposed a joint energy security plan, aiming for a generation capacity exceeding 160,000 MWe by 2030. Pakistan's Nuclear Energy Vision 2050 targets a capacity of 40,000 MWe, with 8,900 MWe expected by 2030. In June 2008, the nuclear complex at Chashma in Punjab Province expanded with the installation of Chashma-III and Chashma–IV reactors, each with 325–340 MWe, costing ₨129 billion, with ₨80 billion from international sources, mainly China. Another agreement for China's assistance was signed in October 2008, seen as a response to the US–India agreement. The project's cost was then US$1.7 billion, with a foreign loan of US$1.07 billion. In 2013, Pakistan established a second nuclear complex in Karachi with plans for additional reactors, similar to Chashma. Electrical energy in Pakistan is generated by various corporations and distributed evenly among the four provinces by the National Electric Power Regulatory Authority (NEPRA).
== Pharmacology == Pimecrolimus is an ascomycin macrolactam derivative. It has been shown in vitro that pimecrolimus binds to FKBP1A and also inhibits calcineurin. Thus pimecrolimus inhibits T-cell activation by inhibiting the synthesis and release of cytokines from T-cells. Pimecrolimus also prevents the release of inflammatory cytokines and mediators from mast cells. Pimecrolimus, like tacrolimus, belongs to the ascomycin class of macrolactam immunosuppressives, acting by the inhibition of T-cell activation by the calcineurin pathway and inhibition of the release of numerous inflammatory cytokines, thereby preventing the cascade of immune and inflammatory signals. Pimecrolimus has a similar mode of action to that of tacrolimus but is more selective, with no effect on dendritic (Langerhans) cells. It has lower permeation through the skin than topical steroids or topical tacrolimus although they have not been compared with each other for their permeation ability through mucosa. In addition, in contrast with topical steroids, pimecrolimus does not produce skin atrophy.
=== Anti-jamming technologies === The British had been aware that the Germans would determine the purpose of the system and attempt to interfere with it, and had designed in a variety of features and methods in order to address some of these issues even as the first stations were being built. The most obvious of these was CH's ability to operate on different frequencies, which was added to allow the stations to avoid any sort of continuous-broadcast interference on their operating frequency. Additionally, the Interference Rejection Unit, or IFRU, allowed the output of the intermediate stages of the amplifiers to be clipped in an attempt to finely tune the receiver to the station's own signals and help reject broadband signals. More complex was a system built into the CH displays, implemented in order to remove spurious signals from unsynchronized jamming pulses. It consisted of two layers of phosphor in the CRT screen, a quick-reacting layer of zinc sulphide below, and a slower "afterglow" layer of zinc cadmium sulphide on top. During normal operation the bright blue signal from the zinc sulphide was visible, and its signal would activate the yellow zinc cadmium sulphide layer, causing an "averaged" signal to be displayed in yellow. To filter out jamming pulses, a yellow plastic sheet was placed in front of the display, rendering the blue display invisible and revealing the dimmer yellow averaged signal. This is the reason many radars from the War through to the 1960s have yellow displays.
Sources: en.wikipedia.org
It targets the growth hormone-releasing hormone receptor on pituitary somatotroph cells. Binding stimulates cyclic AMP signaling and growth hormone secretion. This is the same receptor used by endogenous GHRH.
It does not act directly on adipose tissue as a primary mechanism. Instead, it increases endogenous growth hormone, which then influences lipolysis and fat distribution. The reduction in visceral fat is an indirect pharmacodynamic effect.
Tesamorelin acts upstream at the pituitary to amplify natural pulsatile growth hormone release. Growth hormone injections provide exogenous hormone and bypass pituitary regulation. The two approaches therefore differ in feedback control and hormonal dynamics.
It is a laboratory-made peptide that mimics growth hormone-releasing hormone. It prompts the pituitary gland to release growth hormone and has been studied mainly in adults with HIV-associated lipodystrophy.